聯(lián)系電話
上海勁馬實(shí)驗(yàn)設(shè)備有限公司
中級(jí)會(huì)員·17年
- 聯(lián)系人：
- 馮經(jīng)理
- 電話：
- 021-60521817
- 手機(jī)：
- 13817140470
- 售后：
- 86-021-61107441
- 傳真：
- 86－021－64881400
- 地址：
- 上海市松江區(qū)漕河涇研展路455號(hào)B座
- 個(gè)性化：
- www.shjmsw.com
- 手機(jī)站：
- m.shjmsw.com
- 網(wǎng)址：
- www.shjmsw.com
掃一掃訪問手機(jī)商鋪
人血管素1說明書
Biochem/physiol Actions
Angiopoietin-1 （Ang-1） is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. Recombinant human ANG-1, derived from HeLa cells, is a C-terminal histidine tagged glycoprotein which migrates with an apparent molecular mass of 60.0 – 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein.
Reconstitution
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein （example 0.1% BSA） and store in working aliquots at -20°C to -80°C.
Physical form
Lyophilized from 20mM Sodium Phosphate, pH 7.5 + 200mM NaCl + 5% Trehalose.
General description
Angiopoietin-1 （Ang-1） is a secreted ligand for Tie-2, a tyrosine-kinase receptor expressed primarily on vascular endothelial cells and early hematopoietic cells. Ang-1/ Tie-2 signaling promotes angiogenesis during the development, remodeling, and repair of the vascular system. Transgenic mice lacking expression of either Ang-1 or Tie-2 fail to develop a fully functional cardiovascular system and die before birth. Postnatally, the angiogenic activity of Ang-1/Tie-2 is required during normal tissue repair and remodeling of the female endometrium in the menstrual cycle. Ang-1/Tie-2 signaling appears to be regulated by Angiopoietin-2 （Ang-2）, a natural antagonist for Tie-2 that exerts its effects through an internal autocrine loop mechanism. In addition to suppressing endothelial cell activation by inhibiting the expression of adhesion and inflammatory molecules, Ang-1 enhances endothelial cell survival and capillary morphogenesis, and lessens capillary permeability. As such, Ang-1 has a potential to become an effective therapeutic agent for treating various endothelium disorders, including several severe human pulmonary diseases. The efficacy of cell-based Ang-1 gene therapy for acute lung injury （ALI） has recently been studied in a rat model of ALI （1）. The results of this study show that such therapy can markedly improve lung condition and suggest that Ang-1 therapy may represent a potential new strategy for the treatment and/or prevention of acute respiratory distress injury （ARDI）, a significant cause of morbidity and mortality in critically ill patients. Recombinant human ANG-1, derived from HeLa cells, is a C-terminal histidine tagged glycoprotein which migrates with an apparent molecular mass of 60.0 – 70.0 kDa by SDS-PAGE under reducing conditions. Sequencing analysis shows N-terminal sequences starting with Ser-20 and with Asp-70 of the 498 amino acid precursor protein.
